N-n-hexylazetidine | 1198271-89-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: N-n-hexylazetidine
• 英文别名: 1-Hexylazetidine
• CAS: 1198271-89-4
• 化学式: C₉H₁₉N
• 分子量: 141.257
• InChiKey: DFJJAKZJGLOMAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-(hexylammonio)propyl sulfate 在 potassium hydroxide 作用下， 以 水 为溶剂， 反应 0.25h， 以73%的产率得到N-n-hexylazetidine
  参考文献：
  名称：

  Microwave-assisted synthesis of azetidines in aqueous media

  摘要：

  Simple azetidines are synthesized in good to excellent yields and high purity via cyclization of 3-(ammonio nio)propyl sulfates derived from primary amines and the cyclic sulfate of 1,3-propanediol. A feature of this methodology includes the accelerated synthesis of azetidines in water under the influence of microwave-assisted heating. (C) 2009 Elsevier Ltd. All rights reserved

  DOI：

  10.1016/j.tetlet.2009.09.063

文献信息

• 2-ARYLMETHYLAZETIDINE-CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVE OR ITS SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：Choi Young-Ro

  公开号：US20110118229A1

  公开（公告）日：2011-05-19

  The present invention provides a 2-arylmethylazetidine-carbapenem-3-carboxylic acid ester derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The 2-arylmethylazetidine-carbapenem-3-carboxylic acid ester derivatives or their pharmaceutically acceptable salts show high oral absorption rate, and thus can be orally administered. The active metabolites thereof have a broad spectrum of antibacterial activities against Gram-positive and Gram-negative bacteria and excellent antibacterial activities against methicillin-resistant Staphylococcus aurus (MRSA) and quinolone-resistant strains (QRS). In particular, the acid addition salts of the 2-arylmethylazetidine-carbapenem-3-carboxylic acid ester derivatives are obtained in crystalline forms having excellent stability.

  本发明提供了2-芳基甲基氮杂环戊烯-碳青霉烯-3-羧酸酯衍生物或其药学上可接受的盐，其制备方法以及包含其的制药组合物。2-芳基甲基氮杂环戊烯-碳青霉烯-3-羧酸酯衍生物或其药学上可接受的盐具有高口服吸收率，因此可以口服给药。其活性代谢物对革兰氏阳性和革兰氏阴性细菌具有广谱的抗菌活性，并且对甲氧西林耐药金黄色葡萄球菌（MRSA）和喹诺酮耐药菌株（QRS）具有优异的抗菌活性。特别是，2-芳基甲基氮杂环戊烯-碳青霉烯-3-羧酸酯衍生物的酸加成盐以晶体形式获得，具有优异的稳定性。
• NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION
  申请人：Su Zhuang

  公开号：US20130303438A1

  公开（公告）日：2013-11-14

  The present invention relates to a compound of the formula (I): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing a viral infection using the same.

  本发明涉及公式（I）的化合物或其药学上可接受的盐，其中符号如规范中所定义; 包含相同化合物的制药组合物，使用相同化合物治疗或预防病毒感染的方法。
• Process for the preparation of an azetidine and intermediates therefor
  申请人：A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation)

  公开号：EP0279543A1

  公开（公告）日：1988-08-24

  A novel process is described for preparing azetidine and 2 or 3 methyl and ethyl azetidine free bases by reacting primary arylmethylamine having suitable bulk providing substituents attached to the methyl carbon and an appropriate propane derivative having leaving groups in the one and three position in hot organic solvent containing a non-nucleophilic base and an amount of water sufficient to promote azetidine ring formation to give N-protected-azetidines and deprotecting by hydrogenolysis under acidic conditions to give an acid salt of the azetidines and thereafter flashing off vaporized azetidine from a hot, agitated strong base solution or slurry and condensing to give the liquid azetidine free bases.

  描述了一种制备氮杂环丁烷和 2 或 3 个甲基和乙基氮杂环丁烷游离碱的新工艺，其方法是：在含有非亲核碱和足以促进氮杂环丁烷环形成的水的热有机溶剂中，使在甲基碳上连接有适当的大量提供取代基的伯芳基甲胺和在 1 和 3 位上具有离去基团的适当丙烷衍生物发生反应，得到 N-保护的氮杂环丁烷，然后在酸性条件下通过氢解进行脱保护，得到氮杂环丁烷的酸式盐。在含有非亲核碱和足以促进氮杂环丁烷环形成的水量的热有机溶剂中，使具有与甲基碳相连的适当大量取代基的芳基甲胺和在一和三位上具有离去基团的适当丙烷衍生物发生反应，得到 N-保护-氮杂环丁烷，并在酸性条件下通过氢解进行脱保护，得到氮杂环丁烷的酸式盐，然后从热的强碱溶液或浆液中闪蒸掉汽化的氮杂环丁烷、搅拌的强碱溶液或浆液中闪蒸出汽化的氮杂环丁烷，然后冷凝得到液态氮杂环丁烷游离碱。
• SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS
  申请人：Epizyme Inc

  公开号：EP3519393B1

  公开（公告）日：2022-05-18
• US4870189A
  申请人：——

  公开号：US4870189A

  公开（公告）日：1989-09-26